Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTN3A1 | O00481 | 2/20 | 0.35 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2670343 | 1.00 | BTN3A1 (0.35) | BTN3A1CA14CA12SMN1; SMN2CA1 | |
| SCHEMBL2670209 | 1.00 | BTN3A1 (0.35) | BTN3A1CA14CA12SMN1; SMN2CA1 | |
| SCHEMBL32668778 | 0.81 | BTN3A1 (0.33) | BTN3A1SMN1; SMN2CA1CA2 | |
| SCHEMBL1485422 | 0.81 | BTN3A1 (0.33) | BTN3A1SMN1; SMN2CA1CA2 | |
| SCHEMBL1485424 | 0.81 | BTN3A1 (0.33) | BTN3A1SMN1; SMN2CA1CA2 | |
| SCHEMBL5027923 | 0.81 | GABRR1 (0.34) | BTN3A1 | |
| SCHEMBL9364993 | 0.81 | GABRR1 (0.34) | BTN3A1 | |
| SCHEMBL16840474 | 0.81 | TSHR (0.31) | BTN3A1 | |
| SCHEMBL5027924 | 0.81 | GABRR1 (0.34) | BTN3A1 | |
| SCHEMBL5964084 | 0.81 | CA12 (0.33) | BTN3A1CA14CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170267681-A1 | ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES | MIDCAP FINANCIAL TRUST, AS AGENT | 2017-09-21 | — | — | US | disclosed |
| US-20150291596-A1 | ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES | BIOCRYST PHARMACEUTICALS, INC. | 2015-10-15 | — | — | US | disclosed |
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-22 | — | — | US | disclosed |
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-22 | — | — | US | disclosed |
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2014-05-22 | — | — | US | disclosed |
| US-8618094-B2 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-12-31 | — | — | US | disclosed |
| EP-2097400-B1 | FUSED SUBSTITUTED AMINOPYRROLIDINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2013-07-03 | — | — | EP | disclosed |
| EP-2097400-B1 | FUSED SUBSTITUTED AMINOPYRROLIDINE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2013-07-03 | — | — | EP | disclosed |
| US-20130029977-A9 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2013-01-31 | — | — | US | disclosed |
| US-20130029977-A9 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2013-01-31 | — | — | US | disclosed |
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2012-05-03 | — | — | US | disclosed |
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | DAIICHI SANKYO COMPANY, LIMITED | 2012-05-03 | — | — | US | disclosed |
| US-7968736-B2 | Analogs of discodermolide and dictyostatin-1, intermediates therefor and methods of synthesis thereof | University of Pittsburgh—of the Commonwelth Systems of Higher Education (US) | 2011-06-28 | — | — | US | disclosed |
| EP-2097400-A2 | FUSED SUBSTITUTED AMINOPYRROLIDINE DERIVATIVE | Daiichi Sankyo Company, Limited (JP) | 2009-09-09 | — | — | EP | disclosed |
| US-20090036691-A1 | ANALOGS OF DICODERMOLIDE AND DICTYOSTATIN-1, INTERMEDIATES THEREFOR AND METHODS OF SYNTHESIS THEREOF | PITTSBURGH UNIVERSITY OF - OF THE COMMONWEALTH SYSTEM OF HIGHER | 2009-02-05 | — | — | US | disclosed |
| WO-2008082009-A2 | FUSED SUBSTITUTED AMINOPYRROLIDINE DERIVATIVE | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2008-07-10 | — | — | WO | disclosed |
| US-20060270862-A1 | Analogs of discodermolide and dictyostatin-1, intermediates therefor and methods of synthesis thereof | PITTSBURGH, UNIVERSITY OF | 2006-11-30 | — | — | US | disclosed |
| US-7122686-B2 | Analogs of discodermolide and dictyostatin-1, intermediates therefor and methods of synthesis thereof | UNIVERSITY OF PITTSBURGH (US) | 2006-10-17 | — | — | US | disclosed |
| US-20040186165-A1 | Analogs of discodermolide and dictyostatin-1, intermediates therefor and methods of synthesis thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-09-23 | — | — | US | disclosed |
| WO-2004022552-A1 | ANALOGS OF DISCODERMOLIDE AND DICTYOSTATIN-1, INTERMEDIATES THEREFOR AND METHODS OF SYNTHESIS THEREOF | UNIVERSITY OF PITTSBURGH (US) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036691-A1 | ANALOGS OF DICODERMOLIDE AND DICTYOSTATIN-1, INTERMEDIATES THEREFOR AND METHODS OF SYNTHESIS THEREOF | RRS1, RPS3A, RPS3 | BTN3A1 1581/4885CA14 2961/4885CA12 3912/4885 |
| US-20060270862-A1 | Analogs of discodermolide and dictyostatin-1, intermediates therefor and methods of synthesis thereof | RRS1, RPS6KA3, RPS6KA4 | BTN3A1 1876/4885CA14 3567/4885CA12 4294/4885 |
| US-20120108582-A1 | Fused substituted aminopyrrolidine derivative | NQO2, QDPR, IL4I1 | BTN3A1 4066/4885CA14 3264/4885CA12 3042/4885 |
| US-20150291596-A1 | ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES | RNGTT, DUT, RNMT | BTN3A1 3198/4885CA14 4401/4885CA12 4402/4885 |
| US-20140142096-A1 | Fused Substituted Aminopyrrolidine Derivative | NQO2, QDPR, IL4I1 | BTN3A1 4066/4885CA14 3264/4885CA12 3042/4885 |
| US-20130029977-A9 | Fused substituted aminopyrrolidine derivative | NQO2, QDPR, IL4I1 | BTN3A1 4066/4885CA14 3264/4885CA12 3042/4885 |
| US-20170267681-A1 | ANTIVIRAL AZASUGAR-CONTAINING NUCLEOSIDES | RNGTT, DUT, RNMT | BTN3A1 3198/4885CA14 4401/4885CA12 4402/4885 |
| US-20040186165-A1 | Analogs of discodermolide and dictyostatin-1, intermediates therefor and methods of synthesis thereof | DECR1, RRS1, WEE1 | BTN3A1 1447/4885CA14 3190/4885CA12 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.